Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed informed consent prior to any study specific procedures~* Male or female, aged ≥18 years~* Established documented diagnosis of symptomatic HFrEF (NYHA functional class II-IV), which has been present for at least 2 months~* LVEF≤40%~* Elevated NT-proBNP levels~* Patients should receive background standard of care for HFrEF and be treated according to locally recognized guidelines~* eGFR ≥30 mL/min/1.73 m\^2 (CKD-EPI formula) at enrolment (visit 1)~Exclusion Criteria:~* Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor~* Type 1 diabetes mellitus~* Symptomatic hypotension or systolic BP \<95 mmHg at 2 out of 3 measurements either at visit 1 or visit 2~* Current acute decompensated HF or hospitalization due to decompensated HF \<4 weeks prior to enrolment~* MI, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment~* Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization~* Implantation of a CRT within 12 weeks prior to enrolment or intent to implant a CRT device~* Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization~* HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease~* Symptomatic bradycardia or second or third degree heart block without a pacemaker~* Severe (eGFR \<30 mL/min/1.73 m\^2 by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): Patients will be randomized 1:1 to either dapagliflozin or placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matching dapagliflozin.

Based on this trial design, predict the completion outcome and termination type (if applicable).